Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double blinded, placebo-controlled phase III clinical trial in adult patients with immune thrombocytopenia.

Clinical Trial Description

Approximate 177 patients will be enrolled in study (HMPL-523 2:1 vs Placebo) . ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05029635
Study type Interventional
Source Hutchison Medipharma Limited
Contact Hongyan Yin
Phone 201-20671823
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date October 1, 2021
Completion date November 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT02868060 - Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP) Phase 1/Phase 2
Recruiting NCT04346654 - A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP Phase 2
Not yet recruiting NCT04968899 - IgIV Plus Prednisone vs High-dose Dexamethasone for ITP Phase 3
Terminated NCT01054443 - A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP) Phase 2
Recruiting NCT04915482 - Eltrombopag Combined With Low-dose Rituximab in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Phase 4
Completed NCT00344149 - Rituximab as Second Line Treatment for ITP Phase 3
Recruiting NCT04669600 - A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP) Phase 2
Completed NCT01666795 - Autoantibody Specificity and Response to IVIG in ITP N/A
Recruiting NCT03951623 - The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients Phase 1
Recruiting NCT03975361 - Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE) N/A